Home » RECEPTOPHARM SIGNS LETTER OF INTENT TO BE AQUIRED BY NUTRA PHARMA CORPORATION

RECEPTOPHARM SIGNS LETTER OF INTENT TO BE AQUIRED BY NUTRA PHARMA CORPORATION

June 19, 2006

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that ReceptoPharm has signed a letter of intent to be fully acquired by Nutra Pharma Corp.
Genetic Engineering News

KEYWORDS FDAnews Drug Daily Bulletin

27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
17Feb
Effective Auditing for Manufacturing Quality

RECEPTOPHARM SIGNS LETTER OF INTENT TO BE AQUIRED BY NUTRA PHARMA CORPORATION

Upcoming Events

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Effective Auditing for Manufacturing Quality

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Regeneron’s Antibody Cocktail Shows Efficacy as COVID-19 Treatment

FDA to Review Berkshire’s 510(k) Submission for Remote Drug-Delivery System

Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

Abbott’s Panbio COVID-19 Test Gets Additional CE Marks

The Revised ICH E8: A Guide to New Clinical Trial Requirements